Palavras-chave
Lipoproteína
aterosclerose
hanseníase
aterosclerose
hanseníase
Como Citar
1.
Dalpino D, Magna LA, Opromolla DVA. Avaliação dos níveis de lipídeos, lipoproteínas, apoproteínas e o papel da lipoproteína(a) no desenvolvimento de aterosclerose e alterações fibrinolíticas nos pacientes portadores de hanseníase virchoviana. Hansen. Int. [Internet]. 30º de novembro de 1997 [citado 26º de dezembro de 2024];22(2):20-3. Disponível em: https://periodicos.saude.sp.gov.br/hansenologia/article/view/36452
Resumo
Muitos pacientes portadores de hanseníase virchoviana, após longo tempo de evolução, apresentam alterações dérmicas muito semelhantes aos xantomas e seus exames histológicos mostram numerosos macrófagos carregados de material lipídico. Esses fatos, associados a alterações humorais dos lipídeos descritas na literatura, sugerindo alterações no metabolismo dos mesmos, levou-nos a estudos, visando a estabelecer valores médios em pacientes, utilizando-se de novas determinações lipoprotêicas e de apoproteínas muito mais precisas. A Lipoproteína(a) apresentou valor médio acima de 20 mg/dl em 64,6% dos pacientes, contra 33,3% no grupo controle. O encontro de Lipoproteína(a) aumentada em pacientes portadores de hanseníase virchoviana é importante, porque existe uma comprovada relação entre esta lipoproteína e alterações vasculares tipo ateroscleróticas e distúrbios na fibrinólise.
Referências
1-ALBERS, J. J. ; MARCOVINA, S.M. & LODGE, M.S. The Unique Lipoprotein(a): Properties and Immunochemical Measurement. Clin.Chem., v. 36(12), p. 2019-2026, 1990.
2-ALBERS, J.J. ; WAHL, P.W. ; CABANA, V.G. ; et al. Quantitation of Apolipoprotein A-I of Human Plasma High Density Lipoprotein. Metabolism, v. 25(6), p. 633-644, 1976.
3-AHALEY, S.K. ; SARDESHMUKH, A.S. ; SURYAKAR, A.N.; et al. Correlation of Serum Lipids and Lipoproteins in Leprosy. Indian J. Lepr. , v. 64(1), p. 91-98, 1992.
4-ASSMANN, G. ; SCHRIEWER , H.; SCHMITZ, G.; et al. Quantification of High-Density-Lipoprotein Cholesterol by Precipitation wi th Phosphotungstic
Acid/MgCI2. Clin. Chem., v. 29(12), p. 2026-2030, 1983.
5-BERG, K. ; DAHLEN, G. & BORRESEN, A. Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males. Clin. Genet., v. 16, p. 347-352, 1979
6-BHUSHAM, B. ; KAUR, S.; GEORGE, T.; et al. Serum lipids in leprosy. Lepr. India, v. 52(3), p. 433-439, 1980.
7-BLUM, C.R. ; LEVY, R.I.; EISENBERG,S.; et al. High-Density Lipoprotein Metabolism in Man. I. Clin. Invest., v. 60, p. 795-807, 1977.
8-BROWN, M.S. ; KOVANEN, P.T. & GOLDSTEIN, J.L. Regulation of Plasma Cholesterol by Lipoprotein Receptors. Science, v. 212, p. 628-635, 1981.
9-BROWN, M.S. & GOLDSTEIN, J.L. Lipoprotein Metabolism in the macrophage: Implications for Cholesterol Deposition in Atherosclerosis. Ann. Review Biochem., v. 52, p. 223-261, 1983.
10-CASTELLI, W.P.; DOYLE, J.T.; GORDON, T.; et al. HDL Cholesterol and Other Lipids in Coronary Heart Disease. The Cooperative Lipoprotein
Phenotyping Study. Circulation, v. 55, p. 767-772, 1977.
11-COLDITZ, G.A. ; BONITA, R. ; STAMPFER, M.J.; et al. Cigarette Smoking and Risk of Stroke in Middle-Aged Women. N. 6íg1. I. Med. , v. 318(15), p. 937-941, 1988.
12-DAHLEN, G.H. ; GUYTON, J.R. ; ATTAR, M.; et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary
artery disease documented by angiography. Circulation, v. 74(4), p. 758-765, 1986.
13-EATON, D.L. ; FLESS, G.M. ; KOHR, W.J.; et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc. Natl. Acad. Sci. U.S.A., v. 84, p. 3224-3228, 1987.
14-EDELBERG, J.M. ; GONZALES-GRONOW, M. & PIZZO, S.V. Lipoprotein(a) Inhibits Streptokinase-Mediated Activation of Human Plasminogen.
Biochemistry, v. 28, p. 2370-2374, 1989.
15-EDER, H.A. & GIDEZ, L.I. The Clinical Significance of the Plasma High Density Lipoproteins. Med. Clin. North Am., v. 66(2), p. 431-439, 1982.
16-FRANK, S.L. ; KLISAK, I. ; SPARKES, R.S.; et al. The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the
homologous gene for plasminogen. Hum. Genet., v. 79, p. 352-356, 1988.
17-FUSTER, V. ; BADINOM, L. ; BADINOM, J.J.; et al. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes.(First of Two Parts). N. Engl. I. Med., v. 326(4), p. 242-250, 1992.
18-FUSTER, V.; BADINOM, L.; BADINOM, J.J.; et al. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes.(Second of Two Parts) N. Engl. I. Med., v. 326(5), p. 310-318, 1992.
19-GAUBATZ, J.W.; HEIDEMAN, C. ; GOTTO Jr.; et al. Human Plasma Lipoprotein(a). I. Biol. Chem., v. 258(7), p. 4582-4589, 1983.
20-GIRARD, G. & WOLTZ, H. La cholesterolemie chez les lepreux de Madagascar. Inter. J. Lepr., v. 2(4), p. 492,1934.
21-GONZALES-GRONOW, M.; EDELBERG, J.M. & PIZZO, S.V. Further Characterization of the Cellular Plasminogen Binding Site: Evidence That Plasminogen 2 and Lipoprotein a Compete for the Same Site. Biochemistry, v. 28, p. 2374-2377, 1898.
22-GORDON, T. ; CASTELLI, W.P.; HJORTLAND, M.C.; et al. High Density Lipoprotein As a Protective Factor Against Coronary Heart Disease. The Framinghan Study. Am. I. Med., v. 62, p. 707-14, 1977.
23-GOTT Jr, A.M. A Symposium: New Directions in Tratament of Patients at Risk of Coronary Artery Disease. Am.J.Cardiol., v. 57(14), p. 10-11, 1986.
24-HAJJAR, K.A. ; GAVISH, D. ; BRESLOW, J.L.; et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in
atherosclerosis. Nature, v. 339, p. 303-305, 1989.
25-HAARBO, J. ; HASSAGER, C. ; SCHLEMMER, A.; et al. Influence of smoking, body fat distribution, and alcohol consumption on serum lipids, lipoproteins, and apolipoproteins in early postmenopausal women. Atherosclerosis, v. 84, p. 239-244, 1990.
26-HARIPRASAD, Ch.; RAMA RAO, A.V.S.S.; SYAMASUNDARA, P.; et al. Serum Beta Lipoprotein Levels in Leprosy. Inter. I. Lepr., v. 39(4), p. 896-897, 1970.
27-HAVEL, R.J. ; KANE, J.P. & KASHYAP, M.L. Interchange of Apol ipoproteins betwen Chylomicrons and High Density Lipoproteins during Alimentary Lipemia in Man. I. Clin Invest, v. 52, p. 33-38, 1973.
28-HJERMANN, I. ; HOLME, I.; VELVE BYRE, K. ; et al. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet, v. II, p. 1303-1310, 1981.
29-IZAKI, M. & KON, S. Fibrinolytic phenomenon in erythema nodosum leprosum - with special reference to its pathogenesis and treatment. Abstrat No. 166, Transactions of the Ninth International Leprosy Congress, London, September 1968. Int. 1. Lepr. v. 36(4); p.639, 1968.
30-JADHAV, V.H. ; JADHAV, M.V. ; SAPATNEKAR, S.M.; et al. Fibrinolytic Phenomenon in Leprosy. Indian I. Lepr. , v. 62(2), p. 208-214, 1990.
31-JAIN, V.K. ; VERMA, K.C. & AGGARWAL, S.S. A Study of Serum Fibrinolytic Activity in Erythema Nodosum Leprosum( ENL). Lepr India, v. 55(1): p. 95-107, 1983.
32-KARADI, I. ; KOSTNER, G.M. ; GRIES, A. ; et al. L i p o p r o t e i n ( a ) a n d p l a smi n o g e n a r e immunochemically related. Biochem. Biophys. Acta, v. 960, p. 91-97, 1988.
33-KREMPLER, F. ; KOSTNER, G. ; BOLZANO, K.; et al. Studies on the Metabolism of Lipoprotein Lp(a) In Man. Atherosclerosis, v. 30, p. 57-65, 1978.
34-KREMPLER, F. ; KOSTNER, G.M.; BOLZANO, K.; et al. Turnover of Lipoprotein(a) in Man. I. Clin. Invest., v. 65(6), p. 1483-1490, 1980.
35-KREMPLER, F. ; KOSTNER, G.M. ; ROSCHER, A. ;et al. Studies on the Role of Specific Cell Surface Receptors in the Removal of Lipoprotein(a) in Man. 1. Clin. Invest., v. 71(5), p. 1431-1441, 1983.
36-KUMAR, N. ; SARASWAI, P.K. & SHANKER, A. E s t ima t i o n o f h i g h d e n s i t y l i p o p r o t e i n cholesterol in the diagnosis of lepromatous
leprosy. Ind. . Lepr. , v. 60(4), p. 600-603, 1988.
37-LAKIER, J.B. Smoking and Cardiovascular Disease Am. . Med., v. 93(1A), p. 85-125, 1992.
38-LOPES-VIRELLA, M.F.; STONE, I'.; ELLIS, S.; et al. Cholesterol Determination in High Density Lipoproteins Separated by Three Dif ferent Methods. Clin. Chem., v. 23(5), p. 882-884, 1977.
39-LOSCALZO, J. ; WEINFELD, M. ; FLESS, G.M.; et al. Lipoprotein(a), Fibrin Binding, and Plasminogen Activation. Atherosclerosis, v. 10(2), p. 240-245,
1990.
40-MAEDA, S. ; ABE, A. ; SEISHIMA, M.; et al. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis, v. 78, p. 145-150, 1989.
41-MARANHÃO, R.C. ; ARIE, S. ; VINAGRE, C.G.C. ; et al. Níveis plasmáticos de Lipoproteína(a) em indivíduos normais e portadores de doença coronariana confirmada por cinecoronario-grafia. Arq. Bras. Cardiol, v. 56(2), p. 121-125, 1991.
42-MARTINEZ, T.L.R.; AURIEMO, C.R.C.; BERTINIOLIVEIRA, A.M.; et al. Considerações básicas sobre a bioquímica, metabolismo e avaliação laboratorial das lipoproteínas. Rev. Bras. Pat. Clin., v. 20(6), p.177-184, 1984.
43-MARTINEZ, T.L.R.; PINTO, L.E.S.A.; MALDJIAN, S.; et al. Lipoproteínas-Fisiologia. Laes, v. 61, p. 18. 28, 1989.
44-MARTINEZ, T.L.R. ; PINTO, L.E.S.A.; SILVA, A.M.A.P.N.; et al. Lipoproteínas: formas menos freqüentes de dislipidemias. Laos, v. 64, p.12-18, 1990.
45 -MBEWU, A.D. & DURRINGTON, P.N. L i p o - protein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis.
Atherosclerosis, v. 85, p. 1-14, 1990.
46-McLEAN, J.W. ; TOMLINSON, J.E. ; KUANG, W.I.; et al . cDNA sequ ence of human apol i p oprotei n(a) is homol ogous to plasmi nogen. Nature, v. 300, p.132-137, 1987.
47-MEYERS, W.M. Impairment of Plasma Fibrinolytic Activity in Leprosy Patients. Int. . Lepr. v. 37(4), p. 343-350, 1969.
48- MEYERS, W.M. Plasma Heparin-Precipitable Fraction in Leprosy Patients. Int. . Lepr., v. 36(2): p. 192-202, 1968.
49-MILLER, G.I. & MILLER, N.E. Plasma-high-densitylipoprotein concentration and development of ischaemic heart-disease. Lancet, v. 1: p. 16-19, 1975.
50-MILES, L.A. ; FLESS, G.M. ; LEVIN, E.G. ; et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature, v. 339, v. 301-313, 1989.
51-MONTENEGRO, M.R. - A Aterosclerose em São Paulo. II- Aterosclerose na aorta e nas artérias coronárias. Rev. Inst. Med. Trop. São Paulo , v.9(2), p. 107-124, março-abril, 1967.
52-MONTENEGRO, M.R. Patogenia da Aterosclerose. Laos, v. 69, p. 24-31, 1991.
53-MURAI, A. ; MIYAHARA, T. ; FUJIMOTO, N. ; et al. Lp(a) Lipoprotein as a Risk Factor for Coronary He a r t Di s e a s e a n d Ce r e b r a l In f a r c t i o n .
Atherosclerosis, v. 59, p. 199-204, 1986.
54-OPROMOLLA, D.V.A. História da hanseníase. In: Noções de Hanseníase. Parte I. Hospital Lauro de Souza Lima, 1981: 1-9, 84-95.
55-OPROMOLLA, D.V.A. ; TONELLO, C. ; FLEURY, R.N. & BASTAZINI, I. Embolia Pulmonar no decurso de Reação Hansênica. Hansen. Int, v. 2(2), p. 178-
183, 1977.
56-PARKER, F. Xantomas e Hiperlipidemias- . Am. Acad. Dermatol. v. 13(1), p. 1-30, 1985.
57-RATH DE SOUZA, P. & ALAYON, F. Sobre a presença de lipídios nas lesões cutâneas da lepra. Rev. Brasileira Leprol. v. 10, p. 369-401, 1942.
58-ROGERS, J.H. Coronary thrombosis, cerebral vascular accident and pulmonary embolism in leprosy Int. . Lepr., v. 29(4), p. 538, 1961.
59-SANNAZZARO, C.A.C. & GUNTER HOXTER - Deslipemias. Laes, v. 59, p. 50-61, 1989.
60-SEED, M. ; HOPPICHLER, F. ; REAVELEY, D. ; McCARTHY, S. ; et al . Rel at ion of serum lipoprotein(a) concentration and apolipoprotein(a)
phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. . Med., v. 322(21), p. 1494-1499, 1990.
61-SIEDEL, I. ; HAGELE, E.O.; ZIEGENHORN, J.; et al. Reagent for the Enzymatic Determination of Serum Total Cholesterol with Improved Lipolytic Efficiency. Clin. Chem., v. 29(6), p. 1075-1080, 1983.
62-SRITHARAN, K. ; VENKATESAN, K.; BHARADWAJ, V.P. & RAMU, G. Serum lipids profile in leprosy. Lepr. India, v. 51(4), p. 515-520, 1979.
63-TALL, A.R. & SMALL, D.M. Plasma High Density Lipoproteins. N. Engl. . Med., v. 299(22), p. 1232-1236, 1978.
64-UTERMANN, G. ; HOPPICHLER, F. ; DIEPLINGER, H. ; et al. Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels:
Multipl icative interact ion of two gene loci associated with premature atherosclerosis. Proc. Natl. Acad. Sci. U.S.A.. v. 86, p. 4171-4. 1989.
65-UTERMANN, G. The Mysteries of Lipoprotein(a). Science, v. 246, p. 904-910, 1989.
66-WARNICK, G.R. & ALBERS, J.J. A comprehensive e v a l u a t i o n o f t h e h e p a r i n -ma n g a n e s e precipitation procedure for est imating high
density lipoprotein cholesterol. J. Lipid Res., v. 19, p. 65-76, 1978.
67-WILSON, P. W. F.; GARRISON, R.J. & CASTELLI, W.P. Postmenopausal estrogen use, cigarrette smok i ng, and cardi ovascul ar morbi di t y i n women over 50. The Framinghan Study. N. Engl. . Med., v. 313(17), p. 1038-1043, 1985.
68-WRIGHT, L.C. ; SULLIVAN, D.R. ; MULLER, M. ; et al. Elevated apolipoprotein(a) levels in cancer patients. Int. I. Cancer, v. 43, p. 241-244, 1989
2-ALBERS, J.J. ; WAHL, P.W. ; CABANA, V.G. ; et al. Quantitation of Apolipoprotein A-I of Human Plasma High Density Lipoprotein. Metabolism, v. 25(6), p. 633-644, 1976.
3-AHALEY, S.K. ; SARDESHMUKH, A.S. ; SURYAKAR, A.N.; et al. Correlation of Serum Lipids and Lipoproteins in Leprosy. Indian J. Lepr. , v. 64(1), p. 91-98, 1992.
4-ASSMANN, G. ; SCHRIEWER , H.; SCHMITZ, G.; et al. Quantification of High-Density-Lipoprotein Cholesterol by Precipitation wi th Phosphotungstic
Acid/MgCI2. Clin. Chem., v. 29(12), p. 2026-2030, 1983.
5-BERG, K. ; DAHLEN, G. & BORRESEN, A. Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males. Clin. Genet., v. 16, p. 347-352, 1979
6-BHUSHAM, B. ; KAUR, S.; GEORGE, T.; et al. Serum lipids in leprosy. Lepr. India, v. 52(3), p. 433-439, 1980.
7-BLUM, C.R. ; LEVY, R.I.; EISENBERG,S.; et al. High-Density Lipoprotein Metabolism in Man. I. Clin. Invest., v. 60, p. 795-807, 1977.
8-BROWN, M.S. ; KOVANEN, P.T. & GOLDSTEIN, J.L. Regulation of Plasma Cholesterol by Lipoprotein Receptors. Science, v. 212, p. 628-635, 1981.
9-BROWN, M.S. & GOLDSTEIN, J.L. Lipoprotein Metabolism in the macrophage: Implications for Cholesterol Deposition in Atherosclerosis. Ann. Review Biochem., v. 52, p. 223-261, 1983.
10-CASTELLI, W.P.; DOYLE, J.T.; GORDON, T.; et al. HDL Cholesterol and Other Lipids in Coronary Heart Disease. The Cooperative Lipoprotein
Phenotyping Study. Circulation, v. 55, p. 767-772, 1977.
11-COLDITZ, G.A. ; BONITA, R. ; STAMPFER, M.J.; et al. Cigarette Smoking and Risk of Stroke in Middle-Aged Women. N. 6íg1. I. Med. , v. 318(15), p. 937-941, 1988.
12-DAHLEN, G.H. ; GUYTON, J.R. ; ATTAR, M.; et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary
artery disease documented by angiography. Circulation, v. 74(4), p. 758-765, 1986.
13-EATON, D.L. ; FLESS, G.M. ; KOHR, W.J.; et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc. Natl. Acad. Sci. U.S.A., v. 84, p. 3224-3228, 1987.
14-EDELBERG, J.M. ; GONZALES-GRONOW, M. & PIZZO, S.V. Lipoprotein(a) Inhibits Streptokinase-Mediated Activation of Human Plasminogen.
Biochemistry, v. 28, p. 2370-2374, 1989.
15-EDER, H.A. & GIDEZ, L.I. The Clinical Significance of the Plasma High Density Lipoproteins. Med. Clin. North Am., v. 66(2), p. 431-439, 1982.
16-FRANK, S.L. ; KLISAK, I. ; SPARKES, R.S.; et al. The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the
homologous gene for plasminogen. Hum. Genet., v. 79, p. 352-356, 1988.
17-FUSTER, V. ; BADINOM, L. ; BADINOM, J.J.; et al. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes.(First of Two Parts). N. Engl. I. Med., v. 326(4), p. 242-250, 1992.
18-FUSTER, V.; BADINOM, L.; BADINOM, J.J.; et al. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes.(Second of Two Parts) N. Engl. I. Med., v. 326(5), p. 310-318, 1992.
19-GAUBATZ, J.W.; HEIDEMAN, C. ; GOTTO Jr.; et al. Human Plasma Lipoprotein(a). I. Biol. Chem., v. 258(7), p. 4582-4589, 1983.
20-GIRARD, G. & WOLTZ, H. La cholesterolemie chez les lepreux de Madagascar. Inter. J. Lepr., v. 2(4), p. 492,1934.
21-GONZALES-GRONOW, M.; EDELBERG, J.M. & PIZZO, S.V. Further Characterization of the Cellular Plasminogen Binding Site: Evidence That Plasminogen 2 and Lipoprotein a Compete for the Same Site. Biochemistry, v. 28, p. 2374-2377, 1898.
22-GORDON, T. ; CASTELLI, W.P.; HJORTLAND, M.C.; et al. High Density Lipoprotein As a Protective Factor Against Coronary Heart Disease. The Framinghan Study. Am. I. Med., v. 62, p. 707-14, 1977.
23-GOTT Jr, A.M. A Symposium: New Directions in Tratament of Patients at Risk of Coronary Artery Disease. Am.J.Cardiol., v. 57(14), p. 10-11, 1986.
24-HAJJAR, K.A. ; GAVISH, D. ; BRESLOW, J.L.; et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in
atherosclerosis. Nature, v. 339, p. 303-305, 1989.
25-HAARBO, J. ; HASSAGER, C. ; SCHLEMMER, A.; et al. Influence of smoking, body fat distribution, and alcohol consumption on serum lipids, lipoproteins, and apolipoproteins in early postmenopausal women. Atherosclerosis, v. 84, p. 239-244, 1990.
26-HARIPRASAD, Ch.; RAMA RAO, A.V.S.S.; SYAMASUNDARA, P.; et al. Serum Beta Lipoprotein Levels in Leprosy. Inter. I. Lepr., v. 39(4), p. 896-897, 1970.
27-HAVEL, R.J. ; KANE, J.P. & KASHYAP, M.L. Interchange of Apol ipoproteins betwen Chylomicrons and High Density Lipoproteins during Alimentary Lipemia in Man. I. Clin Invest, v. 52, p. 33-38, 1973.
28-HJERMANN, I. ; HOLME, I.; VELVE BYRE, K. ; et al. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet, v. II, p. 1303-1310, 1981.
29-IZAKI, M. & KON, S. Fibrinolytic phenomenon in erythema nodosum leprosum - with special reference to its pathogenesis and treatment. Abstrat No. 166, Transactions of the Ninth International Leprosy Congress, London, September 1968. Int. 1. Lepr. v. 36(4); p.639, 1968.
30-JADHAV, V.H. ; JADHAV, M.V. ; SAPATNEKAR, S.M.; et al. Fibrinolytic Phenomenon in Leprosy. Indian I. Lepr. , v. 62(2), p. 208-214, 1990.
31-JAIN, V.K. ; VERMA, K.C. & AGGARWAL, S.S. A Study of Serum Fibrinolytic Activity in Erythema Nodosum Leprosum( ENL). Lepr India, v. 55(1): p. 95-107, 1983.
32-KARADI, I. ; KOSTNER, G.M. ; GRIES, A. ; et al. L i p o p r o t e i n ( a ) a n d p l a smi n o g e n a r e immunochemically related. Biochem. Biophys. Acta, v. 960, p. 91-97, 1988.
33-KREMPLER, F. ; KOSTNER, G. ; BOLZANO, K.; et al. Studies on the Metabolism of Lipoprotein Lp(a) In Man. Atherosclerosis, v. 30, p. 57-65, 1978.
34-KREMPLER, F. ; KOSTNER, G.M.; BOLZANO, K.; et al. Turnover of Lipoprotein(a) in Man. I. Clin. Invest., v. 65(6), p. 1483-1490, 1980.
35-KREMPLER, F. ; KOSTNER, G.M. ; ROSCHER, A. ;et al. Studies on the Role of Specific Cell Surface Receptors in the Removal of Lipoprotein(a) in Man. 1. Clin. Invest., v. 71(5), p. 1431-1441, 1983.
36-KUMAR, N. ; SARASWAI, P.K. & SHANKER, A. E s t ima t i o n o f h i g h d e n s i t y l i p o p r o t e i n cholesterol in the diagnosis of lepromatous
leprosy. Ind. . Lepr. , v. 60(4), p. 600-603, 1988.
37-LAKIER, J.B. Smoking and Cardiovascular Disease Am. . Med., v. 93(1A), p. 85-125, 1992.
38-LOPES-VIRELLA, M.F.; STONE, I'.; ELLIS, S.; et al. Cholesterol Determination in High Density Lipoproteins Separated by Three Dif ferent Methods. Clin. Chem., v. 23(5), p. 882-884, 1977.
39-LOSCALZO, J. ; WEINFELD, M. ; FLESS, G.M.; et al. Lipoprotein(a), Fibrin Binding, and Plasminogen Activation. Atherosclerosis, v. 10(2), p. 240-245,
1990.
40-MAEDA, S. ; ABE, A. ; SEISHIMA, M.; et al. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis, v. 78, p. 145-150, 1989.
41-MARANHÃO, R.C. ; ARIE, S. ; VINAGRE, C.G.C. ; et al. Níveis plasmáticos de Lipoproteína(a) em indivíduos normais e portadores de doença coronariana confirmada por cinecoronario-grafia. Arq. Bras. Cardiol, v. 56(2), p. 121-125, 1991.
42-MARTINEZ, T.L.R.; AURIEMO, C.R.C.; BERTINIOLIVEIRA, A.M.; et al. Considerações básicas sobre a bioquímica, metabolismo e avaliação laboratorial das lipoproteínas. Rev. Bras. Pat. Clin., v. 20(6), p.177-184, 1984.
43-MARTINEZ, T.L.R.; PINTO, L.E.S.A.; MALDJIAN, S.; et al. Lipoproteínas-Fisiologia. Laes, v. 61, p. 18. 28, 1989.
44-MARTINEZ, T.L.R. ; PINTO, L.E.S.A.; SILVA, A.M.A.P.N.; et al. Lipoproteínas: formas menos freqüentes de dislipidemias. Laos, v. 64, p.12-18, 1990.
45 -MBEWU, A.D. & DURRINGTON, P.N. L i p o - protein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis.
Atherosclerosis, v. 85, p. 1-14, 1990.
46-McLEAN, J.W. ; TOMLINSON, J.E. ; KUANG, W.I.; et al . cDNA sequ ence of human apol i p oprotei n(a) is homol ogous to plasmi nogen. Nature, v. 300, p.132-137, 1987.
47-MEYERS, W.M. Impairment of Plasma Fibrinolytic Activity in Leprosy Patients. Int. . Lepr. v. 37(4), p. 343-350, 1969.
48- MEYERS, W.M. Plasma Heparin-Precipitable Fraction in Leprosy Patients. Int. . Lepr., v. 36(2): p. 192-202, 1968.
49-MILLER, G.I. & MILLER, N.E. Plasma-high-densitylipoprotein concentration and development of ischaemic heart-disease. Lancet, v. 1: p. 16-19, 1975.
50-MILES, L.A. ; FLESS, G.M. ; LEVIN, E.G. ; et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature, v. 339, v. 301-313, 1989.
51-MONTENEGRO, M.R. - A Aterosclerose em São Paulo. II- Aterosclerose na aorta e nas artérias coronárias. Rev. Inst. Med. Trop. São Paulo , v.9(2), p. 107-124, março-abril, 1967.
52-MONTENEGRO, M.R. Patogenia da Aterosclerose. Laos, v. 69, p. 24-31, 1991.
53-MURAI, A. ; MIYAHARA, T. ; FUJIMOTO, N. ; et al. Lp(a) Lipoprotein as a Risk Factor for Coronary He a r t Di s e a s e a n d Ce r e b r a l In f a r c t i o n .
Atherosclerosis, v. 59, p. 199-204, 1986.
54-OPROMOLLA, D.V.A. História da hanseníase. In: Noções de Hanseníase. Parte I. Hospital Lauro de Souza Lima, 1981: 1-9, 84-95.
55-OPROMOLLA, D.V.A. ; TONELLO, C. ; FLEURY, R.N. & BASTAZINI, I. Embolia Pulmonar no decurso de Reação Hansênica. Hansen. Int, v. 2(2), p. 178-
183, 1977.
56-PARKER, F. Xantomas e Hiperlipidemias- . Am. Acad. Dermatol. v. 13(1), p. 1-30, 1985.
57-RATH DE SOUZA, P. & ALAYON, F. Sobre a presença de lipídios nas lesões cutâneas da lepra. Rev. Brasileira Leprol. v. 10, p. 369-401, 1942.
58-ROGERS, J.H. Coronary thrombosis, cerebral vascular accident and pulmonary embolism in leprosy Int. . Lepr., v. 29(4), p. 538, 1961.
59-SANNAZZARO, C.A.C. & GUNTER HOXTER - Deslipemias. Laes, v. 59, p. 50-61, 1989.
60-SEED, M. ; HOPPICHLER, F. ; REAVELEY, D. ; McCARTHY, S. ; et al . Rel at ion of serum lipoprotein(a) concentration and apolipoprotein(a)
phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. . Med., v. 322(21), p. 1494-1499, 1990.
61-SIEDEL, I. ; HAGELE, E.O.; ZIEGENHORN, J.; et al. Reagent for the Enzymatic Determination of Serum Total Cholesterol with Improved Lipolytic Efficiency. Clin. Chem., v. 29(6), p. 1075-1080, 1983.
62-SRITHARAN, K. ; VENKATESAN, K.; BHARADWAJ, V.P. & RAMU, G. Serum lipids profile in leprosy. Lepr. India, v. 51(4), p. 515-520, 1979.
63-TALL, A.R. & SMALL, D.M. Plasma High Density Lipoproteins. N. Engl. . Med., v. 299(22), p. 1232-1236, 1978.
64-UTERMANN, G. ; HOPPICHLER, F. ; DIEPLINGER, H. ; et al. Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels:
Multipl icative interact ion of two gene loci associated with premature atherosclerosis. Proc. Natl. Acad. Sci. U.S.A.. v. 86, p. 4171-4. 1989.
65-UTERMANN, G. The Mysteries of Lipoprotein(a). Science, v. 246, p. 904-910, 1989.
66-WARNICK, G.R. & ALBERS, J.J. A comprehensive e v a l u a t i o n o f t h e h e p a r i n -ma n g a n e s e precipitation procedure for est imating high
density lipoprotein cholesterol. J. Lipid Res., v. 19, p. 65-76, 1978.
67-WILSON, P. W. F.; GARRISON, R.J. & CASTELLI, W.P. Postmenopausal estrogen use, cigarrette smok i ng, and cardi ovascul ar morbi di t y i n women over 50. The Framinghan Study. N. Engl. . Med., v. 313(17), p. 1038-1043, 1985.
68-WRIGHT, L.C. ; SULLIVAN, D.R. ; MULLER, M. ; et al. Elevated apolipoprotein(a) levels in cancer patients. Int. I. Cancer, v. 43, p. 241-244, 1989
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Downloads
Não há dados estatísticos.
